Navigation Links
Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
Date:2/26/2008

CARLSBAD, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the formation of an inflammatory disease Scientific Advisory Board (SAB). The SAB will provide independent scientific advice and counsel to the Company regarding key decisions relating to the research and development of drugs to treat chronic inflammatory diseases, such as gout and rheumatoid arthritis.

"We have brought together a group of international authorities in gout and arthritis to form the core of our inflammatory disease SAB," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "These experts will play an integral role in guiding our inflammatory product development strategies."

Mark C. Genovese, M.D., is an Associate Professor of Medicine and Co-Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center. Dr. Genovese established a clinical research program at Stanford University that is focused on bench-to-bedside translational medicine in autoimmune diseases and has designed and participated in many trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease and arthritis. He has served as an editor for the textbook, Primary Care Rheumatology, as an associate editor for Kelley's Essentials of Internal Medicine and as an editor on the 7th edition of Kelley's Textbook of Rheumatology.

Arthur Kavanaugh, M.D., is a Professor of Medicine at the University of California, San Diego (UCSD) School of Medicine and the Director of the Center for Innovative Therapy in the UCSD Division of Rheumatology, Allergy, and Immunology. Dr. Kavanaugh has authored more than 240 scientific publications and book chapters. He is on the editorial board for several journals, and has served as peer reviewer for more than a dozen scientific journals. Dr. Kavanaugh is a fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Rheumatology (ACR).

John S. Sundy M.D., Ph.D., is Associate Professor of Medicine and Head of the Section of Allergy and Clinical Immunology in the Division of Pulmonary, Allergy and Critical Care Medicine at Duke University Medical Center. Dr. Sundy is Director of the adult allergy training program at Duke, and is Director of rheumatology research at the Duke Clinical Research Institute. He is board certified in the fields of Rheumatology and Allergy/Immunology and is a national leader in the clinical testing of novel therapies for gout. His additional research interests include translational studies in inflammatory diseases such as asthma and allergic rhinitis.

Ikumi Tamai, Ph.D., is Professor of Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan. His research has focused on the relevance of transporters to the efficacy and toxicity of drugs, as well as the pharmacokinetics of drugs and its application to intestinal drug delivery. Recent areas of study include transporters in the lung, uric acid transporters, drug-induced changes in uric acid transporters, species effect on transporters and drug transports related to intestinal absorption and elimination. He has published over 180 original articles mainly related to transporters.

About Ardea Biosciences, Inc.

Ardea Biosciences of Carlsbad, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including the expected properties and benefits of RDEA806, RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):